CDER’s Galson Says Statin Switches May Be Ready For A Second Look
This article was originally published in The Tan Sheet
Executive Summary
The time may be right for FDA to revisit statins as a possible Rx-to-OTC switch category of drugs, according to Acting CDER Director Steve Galson, MD
You may also be interested in...
FDA’s Crawford Backs Away From Forced Antihistamine Switch Controversy
FDA says it would like to "stimulate" Rx-to-OTC switches where appropriate, but not "force" the policy on drug makers
Pravachol OTC Label Studies, Redefined Population Urged By Cmte.
Bristol-Myers Squibb's Pravachol (pravastatin) 10 mg is an attractive candidate for OTC status, but the company should first conduct additional label comprehension studies and better define the target population for the cholesterol agent, FDA advisory committee members suggested July 14.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC